Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Tree Line Capital Partners is a private credit asset management firm focused on direct lending to lower middle-market companies in North America. The firm provides first lien term loans, unitranche term loans, revolvers, and equity co-investments for acquisitions, recapitalizations, refinancings, expansion projects, and other growth capital needs. It is not a life sciences, biotech, pharma, or healthcare operating company; rather, it is a financial services firm that invests across lower middle-market borrowers. Tree Line was founded in 2014 by Tom Quimby and Jon Schroeder and is headquartered in San Francisco. In 2024, Aflac Global Investments agreed to acquire a 40% stake in the firm while Tree Line retained investment and operational autonomy.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Tree Line Capital Partners.